NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/06/2026
Back to search
Official data from USPTO
XCUBE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
XCUBE
ST13
US500000079320193Class
9, 35, 42, 44
Filing
79320193
Registration
8200099
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
56
Latest update
08/06/2026
Trademark type
Word
Nice classes
9, 35, 42, 44
Filing date
02/25/2021
Registration date
04/07/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/07/2026
Last transaction
08/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DE
Examiner
IN, SUNG HYUN
Law office
L30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Immatics Biotechnologies GmbH
Representatives
Anna Kurian Shaw Hogan Lovells US LLP
Technical classification
Nice Classes
Class 9Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Recorded bioinformatics software for data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded graphical user interface software for data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded artificial intelligence and machine learning software for genome analysisdeveloping personal treatment strategies for patients with diagnosed canceranalyzingscreeningidentifyingquantifyinginterpreting data in the field of mass spectrometry and next-generation sequencing (NGS); electronic databases for bioinformatic purposes; next-generation sequencing (NGS) data processor; bioinformatics data processor; none of the foregoing in connection with HVAC systems or components thereof
Class 35
Compilation of statistical data and models with respect to cancer treatment and cancer diagnosis
Class 42
Computer programming in the medicalpharmaceutical and biotechnological field; database design in the medicalpharmaceutical and biotechnological field; maintenance of database software in the medicalpharmaceuticalbiotechnological field; programming of software for importing and managing data in the medicalpharmaceuticalbiotechnological field; information technology IT consulting services for the pharmaceutical and healthcare industries relating to data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; computer programming for data processing; conducting evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technologycancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials in the field of pharmaceuticals for the treatment and prevention of cancer; providing scientific molecular and genomic information for medical and clinical researchfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; research and development of medicines and diagnostic agents for cancer treatment and cancer diagnosis; providing scientific advice in the fields of cancer biologycancer treatmentpharmaceutical side effectsgenomicscancer medicine and translational medicine; providing scientific analysis in the field of next-generation sequencing (NGS) with respect to the analysis and interpretation of genomic data obtained from cancer patients; providing an onlinenon-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; research and development services in the field of immunology; none of the foregoing in connection with HVAC systems or components thereof
Class 44
Medical and pharmaceutical consultancy services
Publications
History of USPTO decisions and trademark events.
56 publications found
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/07/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/07/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
04/07/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/17/2026
PUBO
PUBLISHED FOR OPPOSITION
02/17/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/11/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/23/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/06/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/06/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/08/2025
GNRT
NON-FINAL ACTION E-MAILED
07/08/2025
CNRT
NON-FINAL ACTION WRITTEN
07/08/2025
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
05/16/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/15/2024
GNSL
LETTER OF SUSPENSION E-MAILED
11/15/2024
CNSL
SUSPENSION LETTER WRITTEN
11/15/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
04/20/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
03/29/2024
DOCK
ASSIGNED TO EXAMINER
03/29/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
03/25/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
09/25/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/14/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
02/27/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/22/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/22/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/30/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/30/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
11/28/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/02/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/02/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/02/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/02/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/07/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/13/2022
GNSL
LETTER OF SUSPENSION E-MAILED
05/13/2022
CNSL
SUSPENSION LETTER WRITTEN
05/13/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2022
ALIE
ASSIGNED TO LIE
05/10/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/06/2022
RFNT
REFUSAL PROCESSED BY IB
11/29/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/08/2021
RFRR
REFUSAL PROCESSED BY MPU
11/08/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/14/2021
CNSL
SUSPENSION LETTER WRITTEN
10/13/2021
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
10/07/2021
MAFR
APPLICATION FILING RECEIPT MAILED
09/24/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/22/2021
CNSL
SUSPENSION LETTER WRITTEN
09/21/2021
DOCK
ASSIGNED TO EXAMINER
09/21/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/20/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/16/2021
Continuous trademark protection
Get notified about every new filing that threatens XCUBE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.